Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

Stopped early · Phase 2

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.

Key facts

Study ID
NCT00615784
Run by
Abramson Cancer Center at Penn Medicine
People needed
24
Starts
2010-05-25
Expected to finish
2013-11-08
Last updated by the study team
2020-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.